Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Want to cut your energy bills? Here’s how five experts are doing it 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
TUCSON, Ariz., Feb. 23, 2017 -- Accelerate Diagnostics, Inc. today announced it will report preliminary fourth-quarter and full year 2016 financial results on Monday, February 27th, 2017.
President and Chief Executive Officer, Lawrence Mehren, joined by Steve Reichling, Chief Financial Officer, will host a conference call to review the results at 4:15 p.m. ET.
Fourth quarter and full year audited financial results will be filed on Form 10-K through the company’s website at http://ir.axdx.com and through the Securities and Exchange Commission's (SEC) website at http://www.sec.gov.
The company is completing its financial closing and auditing procedures for the fiscal year ended December 31, 2016, and these preliminary results are estimates. Investors are cautioned not to place undue reliance on preliminary estimates in the event of material changes.
Conference Call
To participate in the conference call, dial +1.877.883.0383 and enter the conference ID: 2997883.
International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (international) using access code 10101155 until March 14, 2017.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (“Accelerate Diagnostics,”) (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and hospital acquired infections. The company's fully automated Accelerate Pheno™ system, and direct from positive blood culture Accelerate PhenoTest™ BC kit, leverage a suite of technologies to eliminate the lengthy culture and sample preparation steps required prior to testing. Using proprietary molecular identification methods and morphokinetic cellular analysis (MCA), the solution aims to reduce the time that clinicians must wait for quantitative antimicrobial susceptibility results necessary for optimal antibiotic selection, dosing, and infusion strategy, called minimum inhibitory concentrations, or MICs.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its products or technology, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, about our projections as to when certain key business milestones may be achieved, including obtaining marketing authorization by the FDA of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures, the commercial launch of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures, the potential of our technology, the growth of the market, our estimates as to the size of our market opportunity and potential pricing, our competitive position and estimates of time reduction to results, and our future development plans and growth strategy. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned “Risk Factors” in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 9, 2016, and in any other reports that we file with the Securities and Exchange Commission from time to time. In addition, the company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
Investors May Contact: Laura Pierson, Accelerate Diagnostics, +1 520 365-3100 [email protected] Reporters May Contact: Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100 [email protected]
